Daiichi Sankyo launches new blood thinner in U.K.; AbbVie's Imbruvica approved for new use in Europe;

@FiercePharma: ImmuCell boosts Q2 sales guidance as inventory management improves. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: FDA says China staffer Dr. Lixia Wang was key to negotiating deal for more FDA inspection staff in China. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: AstraZeneca grabs $215M for GI drug rights in latest cash-generating deal. Article | Follow @CarlyHFierce

> Daiichi Sankyo has launched its bloodthinner Lixiana in the U.K. Report

> AbbVie ($ABBV) says the European Commission has approved its Imbruvica as the first treatment in the European Union for treating the rare slow-growing blood cancer, Waldenstrom's macroglobulinemia (WM). Release

> Indian drugmaker Cipla has added to its board Samina Vaziralli, niece of Cipla Chairman YK Hamied, as the next generation of the Hamied family gets involved. Report

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: CombiMatrix coasts toward growth with renewed sales push. Report | Follow @FierceMedDev

@StacyALawrence: Go big or go home: A call for FierceMedicalDevices' 2015 Fierce 15 nominations. ICYMI | Follow @StacyALawrence

@EmilyWFierce: Natera joins forces with University College London for lung cancer study. FierceDiagnostics story | Follow @EmilyWFierce

> Smith & Nephew strikes again, bolstering emerging markets with Russian trauma and orthopedics buy. Story

> Xagenic ropes in $15M for point-of-care testing system. Article

> CMS to test new reimbursement system for hip and knee replacements in the U.S. More

Biotech News

@FierceBiotech: 21st Century drug bill triggers a DC dust-up over relaxed development regs. Report | Follow @FierceBiotech

@JohnCFierce: EuroBiotech: KDEV halves portfolio value, U.K. life sci funding hits 10-year high, CF gene therapy on the block. Report | Follow @JohnCFierce

@DamianFierce: ICYMI: Patrick Soon-Shiong tacitly creates another company every time he does anything. NantKwest?! Release | Follow @DamianFierce

> Sanofi cozies up to top-tier labs with new R&D partnering effort. News

> Third Rock's GBT swings for a $115M IPO to push its pill for sickle cell. Article

> Woodford backs ReNeuron's $106M fundraise for cell therapy R&D. Report

And Finally... Naps may improve frustration tolerance, a new study says. More

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.